These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 22049529)

  • 21. Patient-derived first generation xenografts of non-small cell lung cancers: promising tools for predicting drug responses for personalized chemotherapy.
    Dong X; Guan J; English JC; Flint J; Yee J; Evans K; Murray N; Macaulay C; Ng RT; Gout PW; Lam WL; Laskin J; Ling V; Lam S; Wang Y
    Clin Cancer Res; 2010 Mar; 16(5):1442-51. PubMed ID: 20179238
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers.
    Fichtner I; Rolff J; Soong R; Hoffmann J; Hammer S; Sommer A; Becker M; Merk J
    Clin Cancer Res; 2008 Oct; 14(20):6456-68. PubMed ID: 18927285
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The radiosensitizing activity of the SMAC-mimetic, Debio 1143, is TNFα-mediated in head and neck squamous cell carcinoma.
    Matzinger O; Viertl D; Tsoutsou P; Kadi L; Rigotti S; Zanna C; Wiedemann N; Vozenin MC; Vuagniaux G; Bourhis J
    Radiother Oncol; 2015 Sep; 116(3):495-503. PubMed ID: 26096848
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Endogenously released Smac is insufficient to mediate cell death of human lung carcinoma in response to etoposide.
    Bartling B; Lewensohn R; Zhivotovsky B
    Exp Cell Res; 2004 Aug; 298(1):83-95. PubMed ID: 15242764
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prospective randomized study of four novel chemotherapy regimens in patients with advanced nonsmall cell lung carcinoma: a minnie pearl cancer research network trial.
    Greco FA; Gray JR; Thompson DS; Burris HA; Erland JB; Barton JH; Litchy S; Houston GA; Butts JA; Webb C; Scott C; Hainsworth JD
    Cancer; 2002 Sep; 95(6):1279-85. PubMed ID: 12216096
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Smac peptide potentiates TRAIL- or paclitaxel-mediated ovarian cancer cell death in vitro and in vivo.
    Mao HL; Pang Y; Zhang X; Yang F; Zheng J; Wang Y; Liu P
    Oncol Rep; 2013 Feb; 29(2):515-22. PubMed ID: 23151974
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SMAC mimetic Debio 1143 synergizes with taxanes, topoisomerase inhibitors and bromodomain inhibitors to impede growth of lung adenocarcinoma cells.
    Langdon CG; Wiedemann N; Held MA; Mamillapalli R; Iyidogan P; Theodosakis N; Platt JT; Levy F; Vuagniaux G; Wang S; Bosenberg MW; Stern DF
    Oncotarget; 2015 Nov; 6(35):37410-25. PubMed ID: 26485762
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): carboplatin/gemcitabine followed by paclitaxel or cisplatin/vinorelbine followed by docetaxel.
    Edelman MJ; Clark JI; Chansky K; Albain K; Bhoopalam N; Weiss GR; Giguere JK; Kelly K; Crowley J; Gandara DR
    Clin Cancer Res; 2004 Aug; 10(15):5022-6. PubMed ID: 15297403
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study.
    Kubota K; Kawahara M; Ogawara M; Nishiwaki Y; Komuta K; Minato K; Fujita Y; Teramukai S; Fukushima M; Furuse K;
    Lancet Oncol; 2008 Dec; 9(12):1135-42. PubMed ID: 19013107
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Second-line paclitaxel/carboplatin versus vinorelbine/carboplatin in patients who have advanced non-small-cell lung cancer pretreated with non-platinum-based chemotherapy: a multicenter randomized phase II study.
    Pallis AG; Syrigos K; Kotsakis A; Karachaliou N; Polyzos A; Chandrinos V; Varthalitis I; Christophyllakis C; Ardavanis A; Vamvakas L; Vardakis N; Saridaki Z; Samonis G; Giassas S; Georgoulias V; Agelaki S
    Clin Lung Cancer; 2011 Mar; 12(2):100-5. PubMed ID: 21550556
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Key necroptotic proteins are required for Smac mimetic-mediated sensitization of cholangiocarcinoma cells to TNF-α and chemotherapeutic gemcitabine-induced necroptosis.
    Akara-Amornthum P; Lomphithak T; Choksi S; Tohtong R; Jitkaew S
    PLoS One; 2020; 15(1):e0227454. PubMed ID: 31914150
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Smac mimetics can provoke lytic cell death that is neither apoptotic nor necroptotic.
    Miles MA; Caruso S; Baxter AA; Poon IKH; Hawkins CJ
    Apoptosis; 2020 Aug; 25(7-8):500-518. PubMed ID: 32440848
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel second mitochondria-derived activator of caspases (Smac) mimetic compounds sensitize human leukemic cell lines to conventional chemotherapeutic drug-induced and death receptor-mediated apoptosis.
    Servida F; Lecis D; Scavullo C; Drago C; Seneci P; Carlo-Stella C; Manzoni L; Polli E; Lambertenghi Deliliers G; Delia D; Onida F
    Invest New Drugs; 2011 Dec; 29(6):1264-75. PubMed ID: 20614162
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Therapeutic strategies in advanced non-small cell bronchial cancers: platin-based combinations].
    Fournel P
    Rev Pneumol Clin; 2002 Nov; 58(5 Pt 2):3S42-7. PubMed ID: 12538935
    [No Abstract]   [Full Text] [Related]  

  • 35. Birinapant (TL32711), a bivalent SMAC mimetic, targets TRAF2-associated cIAPs, abrogates TNF-induced NF-κB activation, and is active in patient-derived xenograft models.
    Benetatos CA; Mitsuuchi Y; Burns JM; Neiman EM; Condon SM; Yu G; Seipel ME; Kapoor GS; Laporte MG; Rippin SR; Deng Y; Hendi MS; Tirunahari PK; Lee YH; Haimowitz T; Alexander MD; Graham MA; Weng D; Shi Y; McKinlay MA; Chunduru SK
    Mol Cancer Ther; 2014 Apr; 13(4):867-79. PubMed ID: 24563541
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Smac mimetics in combination with TRAIL selectively target cancer stem cells in nasopharyngeal carcinoma.
    Wu MS; Wang GF; Zhao ZQ; Liang Y; Wang HB; Wu MY; Min P; Chen LZ; Feng QS; Bei JX; Zeng YX; Yang D
    Mol Cancer Ther; 2013 Sep; 12(9):1728-37. PubMed ID: 23699656
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Smac mimetic bypasses apoptosis resistance in FADD- or caspase-8-deficient cells by priming for tumor necrosis factor α-induced necroptosis.
    Laukens B; Jennewein C; Schenk B; Vanlangenakker N; Schier A; Cristofanon S; Zobel K; Deshayes K; Vucic D; Jeremias I; Bertrand MJ; Vandenabeele P; Fulda S
    Neoplasia; 2011 Oct; 13(10):971-9. PubMed ID: 22028622
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modulation of Respiration and Mitochondrial Dynamics by SMAC-Mimetics for Combination Therapy in Chemoresistant Cancer.
    Hagenbuchner J; Oberacher H; Arnhard K; Kiechl-Kohlendorfer U; Ausserlechner MJ
    Theranostics; 2019; 9(17):4909-4922. PubMed ID: 31410190
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antitumor activity of lobaplatin alone or in combination with antitubulin agents in non-small-cell lung cancer.
    Xie CY; Xu YP; Jin W; Lou LG
    Anticancer Drugs; 2012 Aug; 23(7):698-705. PubMed ID: 22441567
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibitor of Apoptosis Protein-1 Regulates Tumor Necrosis Factor-Mediated Destruction of Intestinal Epithelial Cells.
    Grabinger T; Bode KJ; Demgenski J; Seitz C; Delgado ME; Kostadinova F; Reinhold C; Etemadi N; Wilhelm S; Schweinlin M; Hänggi K; Knop J; Hauck C; Walles H; Silke J; Wajant H; Nachbur U; W Wei-Lynn W; Brunner T
    Gastroenterology; 2017 Mar; 152(4):867-879. PubMed ID: 27889570
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.